
A new Canadian drug to treat vaginal atrophy and female sexual dysfunction is being developed by a new partnership between Bayer Inc and EndoCeutics Inc, who are based in Quebec. The deal, believed to be worth up to three hundred and thirty million dollars, was revealed on Tuesday and concerns the Phase III development and marketing of the new Canada drug Dehydroepiandrosterone, otherwise known as DHEA. It could cost up to three hundred and thirty million to finance research costs and pay for clinical trials of the Canadian drug in both Canada and the United States. DHEA is believed to be a major factor in menopausal problems for women, decreased levels of which can cause vaginal atrophy and sexual dysfunction. “Up to seventy five percent...